OBJECTIVE: This trial evaluated the efficacy of an HIV-intervention condition, relative to a health-promotion condition, in reducing incidence of nonviral sexually transmitted infections (STIs; Chlamydia, gonorrhea, and trichomoniasis), oncogenic human papillomavirus (HPV) subtypes 16 and 18, sexual concurrency, and other HIV-associated behaviors over a 12-month period. DESIGN: Randomized-controlled trial. Data analysts blinded to treatment allocation. SETTING: Kaiser Permanente, GA. SUBJECTS: A random sample of 848 African American women. INTERVENTION: The two 4-hour HIV intervention sessions were based on Social Cognitive Theory and the Theory of Gender and Power. The intervention was designed to enhance participants' self-sufficiency and attitudes and skills associated with condom use. The HIV intervention also encouraged STI testing and treatment of male sex partners and reducing vaginal douching and individual and male partner concurrency. MAIN OUTCOME MEASURE: Incident nonviral STIs. RESULTS: In generalized estimating equations' analyses, over the 12-month follow-up, participants in the HIV intervention, relative to the comparison, were less likely to have nonviral incident STIs (odds ratio [OR] = 0.62; 95% confidence interval [CI]: 0.40 to 0.96; P = 0.033) and incident high-risk HPV infection (OR = 0.37; 95% CI: 0.18 to 0.77; P = 0.008) or concurrent male sex partners (OR = 0.55; 95% CI: 0.37 to 0.83; P = 0.005). In addition, intervention participants were less likely to report multiple male sex partners, more likely to use condoms during oral sex, more likely to inform their main partner of their STI test results, encourage their main partner to seek STI testing, report that their main partner was treated for STIs, and report not douching. CONCLUSIONS: This is the first trial to demonstrate that an HIV intervention can achieve reductions in nonviral STIs, high-risk HPV, and individual concurrency.
RCT Entities:
OBJECTIVE: This trial evaluated the efficacy of an HIV-intervention condition, relative to a health-promotion condition, in reducing incidence of nonviral sexually transmitted infections (STIs; Chlamydia, gonorrhea, and trichomoniasis), oncogenic human papillomavirus (HPV) subtypes 16 and 18, sexual concurrency, and other HIV-associated behaviors over a 12-month period. DESIGN: Randomized-controlled trial. Data analysts blinded to treatment allocation. SETTING: Kaiser Permanente, GA. SUBJECTS: A random sample of 848 African American women. INTERVENTION: The two 4-hour HIV intervention sessions were based on Social Cognitive Theory and the Theory of Gender and Power. The intervention was designed to enhance participants' self-sufficiency and attitudes and skills associated with condom use. The HIV intervention also encouraged STI testing and treatment of male sex partners and reducing vaginal douching and individual and male partner concurrency. MAIN OUTCOME MEASURE: Incident nonviral STIs. RESULTS: In generalized estimating equations' analyses, over the 12-month follow-up, participants in the HIV intervention, relative to the comparison, were less likely to have nonviral incident STIs (odds ratio [OR] = 0.62; 95% confidence interval [CI]: 0.40 to 0.96; P = 0.033) and incident high-risk HPV infection (OR = 0.37; 95% CI: 0.18 to 0.77; P = 0.008) or concurrent male sex partners (OR = 0.55; 95% CI: 0.37 to 0.83; P = 0.005). In addition, intervention participants were less likely to report multiple male sex partners, more likely to use condoms during oral sex, more likely to inform their main partner of their STI test results, encourage their main partner to seek STI testing, report that their main partner was treated for STIs, and report not douching. CONCLUSIONS: This is the first trial to demonstrate that an HIV intervention can achieve reductions in nonviral STIs, high-risk HPV, and individual concurrency.
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Nicole Crepaz; Khiya J Marshall; Latrina W Aupont; Elizabeth D Jacobs; Yuko Mizuno; Linda S Kay; Patricia Jones; Donna Hubbard McCree; Ann O'Leary Journal: Am J Public Health Date: 2009-09-17 Impact factor: 9.308
Authors: R Scott McClelland; Barbra A Richardson; Wisal M Hassan; Vrasha Chohan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Walter Jaoko; Jeckoniah O Ndinya-Achola; Jared M Baeten; Ann E Kurth; King K Holmes Journal: J Infect Dis Date: 2008-05-15 Impact factor: 5.226
Authors: M L Kamb; M Fishbein; J M Douglas; F Rhodes; J Rogers; G Bolan; J Zenilman; T Hoxworth; C K Malotte; M Iatesta; C Kent; A Lentz; S Graziano; R H Byers; T A Peterman Journal: JAMA Date: 1998-10-07 Impact factor: 56.272
Authors: Laura M Mercer Kollar; Teaniese L Davis; Jennifer L Monahan; Jennifer A Samp; Valerie B Coles; Erin L P Bradley; Jessica McDermott Sales; Sarah K Comer; Timothy Worley; Eve Rose; Ralph J DiClemente Journal: Health Educ Behav Date: 2016-05-10
Authors: Wendee M Wechsberg; Felicia A Browne; William A Zule; Scott P Novak; Irene A Doherty; Tracy L Kline; Monique G Carry; Jerris L Raiford; Jeffrey H Herbst Journal: J Child Adolesc Subst Abuse Date: 2017-02-08
Authors: C Hendricks Brown; David C Mohr; Carlos G Gallo; Christopher Mader; Lawrence Palinkas; Gina Wingood; Guillermo Prado; Sheppard G Kellam; Hilda Pantin; Jeanne Poduska; Robert Gibbons; John McManus; Mitsunori Ogihara; Thomas Valente; Fred Wulczyn; Sara Czaja; Geoff Sutcliffe; Juan Villamar; Christopher Jacobs Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Monica L Kasting; Anthony D Cox; Dena Cox; Kenneth H Fife; Barry P Katz; Gregory D Zimet Journal: BMC Med Date: 2014-11-06 Impact factor: 8.775
Authors: Sara J Czaja; Thomas W Valente; Sankaran N Nair; Juan A Villamar; C Hendricks Brown Journal: Implement Sci Date: 2016-05-17 Impact factor: 7.327
Authors: Maria Grandahl; Andreas Rosenblad; Christina Stenhammar; Tanja Tydén; Ragnar Westerling; Margareta Larsson; Marie Oscarsson; Bengt Andrae; Tina Dalianis; Tryggve Nevéus Journal: BMJ Open Date: 2016-01-27 Impact factor: 2.692